GlassScriptPhysician profile
Craig J Campbell
NPI 1295712404
$1,982.70
in general payments reported to CMS, 2019-2025
22 companies · $80.74 in 2025
The $80.74 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $91.96 · 2021: $139 · 2022: $414 · 2023: $449 · 2024: $446 · 2025: $80.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $806.67 | 2019-2024 | Augment Injectable, Prophecy, Hoffmann |
| Paratek Pharmaceuticals, INC. | $239.47 | 2022-2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $148.54 | 2019-2023 | Jublia |
| Integra Lifesciences Corporation | $137.89 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Journey Medical Corporation | $64.69 | 2019-2024 | |
| Melinta Therapeutics, LLC | $63.90 | 2019-2021 | |
| Abbvie INC. | $60.01 | 2023-2024 | Dalvance |
| Kowa Pharmaceuticals America, INC. | $58.99 | 2022-2023 | Seglentis |
| Sebela Pharmaceuticals INC. | $54.58 | 2022-2023 | Naftin |
| Sandoz INC. | $49.70 | 2019 | |
| Polynovo North America LLC | $48.15 | 2025 | Novosorb Btm |
| Smith+Nephew, INC. | $45.55 | 2019-2024 | Collagenase Santyl |
| Zimmer Biomet Holdings, INC. | $35.93 | 2022 | |
| Tactile Systems Technology INC | $32.29 | 2019-2025 | Nimbl, Flexitouch Plus |
| Pfizer INC. | $27.29 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $27.05 | 2023 | |
| Axogen | $25.00 | 2024 | Axoguard Ha+ Nerve Protector, Axoguard Nerve Connector, Avance Nerve Graft |
| Averitas Pharma INC. | $19.90 | 2024 | Qutenza |
| Novum Pharma, LLC | $17.40 | 2019 | |
| Merck Sharp & Dohme LLC | $15.03 | 2019 | |
| Advanced Oxygen Therapy INC. | $4.67 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$179,743.04 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.